Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859202 | 0.71 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL29228732 | 0.60 | — | — | |
| SCHEMBL6923786 | 0.59 | HCRTR1 (0.52) | CHRNA7HCRTR1HCRTR2 | |
| SCHEMBL27055548 | 0.58 | CHRNA7 (0.42) | CHRNA4CHRNB2CHRNA7 | |
| SCHEMBL24192089 | 0.57 | BPTF (0.40) | CHRNA4CHRNB2CHRNA7HCRTR1HCRTR2 | |
| SCHEMBL6925544 | 0.57 | BPTF (0.40) | CHRNA4CHRNB2CHRNA7HCRTR1HCRTR2 | |
| SCHEMBL1670922 | 0.56 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL20510363 | 0.56 | BPTF (0.52) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21963537 | 0.56 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL29117985 | 0.56 | HCRTR1 (0.51) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170368035-A1 | 5,5-Bicyclic Oxazole Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368035-A1 | 5,5-Bicyclic Oxazole Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | PDE8B 2196/4885CHRNA4 99/4885CHRNB2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.